ARCHIVES

FDA examining endpoints for approval of cancer therapies, potential departure from survival as the gold standard, Oncology Division Director Richard Pazdur says in interview.

This article is from The Cancer Letter archive.

Vol. 29 No. 41 | November 7, 2003

Download PDF Visit The Full Archive

Related Articles

Risk-Benefit Analysis Advised Prior To Hormone Therapy

August 27, 2010

Study: Freezing Secondary Tumors Helpful in Metastatic Breast Cancer

March 30, 2012

In Brief: Gramm-Rudman-Hollings Could Slash NCI Budget By $650 Million; Holleb Retires From ‘Ca’

July 27, 1990

In Brief: ACS to Spend Record $85 Million On Research: AACR To Honor Hanafusa, DeVita, Barbacid

March 14, 1986

In Congress: HHS Funding Bill Vetoed, Congress, White House Negotiating on Budget

November 12, 1999

NCI Picks Duke To Lead caBIG’s Knowledge Center For Clinical Trials.

July 3, 2008